Detection of circulating tumor-DNA as a 'liquid biopsy' in patients with Ewing Sarcoma and PNET: a pilot study

• Conditions: Ewing-Sarcoma (C41.9)primitive neuroectodermal tumor (C71.9); C41.9; C71.9; Bone and articular cartilage, unspecified; Brain, unspecified

• Registration Number: DRKS00009029
• Lead Sponsor: niversitätsklinikum Freiburg

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2015-11-03
• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: Recruiting withdrawn before recruiting started
• Sex: All
• Target Recruitment: 30

Inclusion Criteria

Ewing-Sarcoma /PNET

Exclusion Criteria

other malign tumors, systemic diseases

Study & Design

• Study Type: observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Detection of tumorspecific DNA in the peripheral blood of patients with Ewing-Sarcoma/ PNET

Secondary Outcome Measures

Name	Time	Method
Detection of a tumorspecific miRNA signature in the peripheral blood of patients with Ewing-Sarcoma/ PNET